RxDoctor Payments Data

Shibu Thomas, MD

Pulmonary Disease · Dallas, TXNPI 1366402265

Payments from drug & device makers

$54,232in general payments, 2019–2025

Across 14 payments — averaging $3873.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$54K
  • Abbott$201
  • Intuitive Surgical$142
  • Merck$105
  • Philips North America LLC$45
  • CSL Behring$28
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$53,669
Abbott3$201
Intuitive Surgical1$142
Merck1$105
Philips North America LLC2$45
CSL Behring2$28
Boehringer Ingelheim1$24
ERBE USA Inc1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,232 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$29,150
Medicare patients
86
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →